Infectious Disease

Results presented on investigational West Nile virus vaccine

Published in Vaccine Weekly, June 15th, 2005

Acambis plc (ACM, ACAM) announced that Thomas Monath, MD, chief scientific officer of Acambis, presented the results of a phase I clinical trial of the company's West Nile virus vaccine candidate, ChimeriVax-West Nile, at the National Foundation for Infectious Disease's (NFID) 8th Annual Conference on Vaccine Research.

The meeting was held at the Baltimore Marriott Inner Harbor Hotel in Baltimore, Maryland. Since emerging in the United States in 1999, West Nile virus has caused more than 16,000 cases of West Nile disease and 634 deaths.

Conducted under a U.S. Food and Drug Administration (FDA) Investigational New Drug application, Acambis evaluated...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-06-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry